Key Highlights
- Entact Bio appoints Ruben Tommasi, Ph.D., as Chief Scientific Officer.
- Dr. Tommasi brings 30 years of drug discovery leadership across multiple therapeutic areas.
- Tommasi previously served at Dunad Therapeutics and Entasis Therapeutics, driving successful clinical outcomes.
- Entact Bio focuses on precision medicines that enhance beneficial protein function via the Encompass™ platform.
Source: Business Wire
Notable Quotes
- “We’re thrilled to welcome Ruben, who brings deep expertise in drug discovery and has a proven record in successfully advancing compounds from program inception to clinical development and regulatory approval.” — Victoria Richon, Ph.D., CEO at Entact Bio
- “I was very attracted to the innovative modality Entact is developing as it holds tremendous potential to pursue new, undrugged targets believed to be beneficial against disease.” — Ruben Tommasi, Ph.D., Chief Scientific Officer at Entact Bio
SoHC's Take
The appointment of Dr. Ruben Tommasi as Chief Scientific Officer marks a pivotal moment for Entact Bio. His extensive experience in drug discovery, particularly in progressing compounds through to FDA approval, will likely accelerate the development of Entact’s innovative ENTAC™ medicines. With a proven track record across multiple therapeutic areas, Dr. Tommasi’s leadership will strengthen the company’s ability to explore novel therapeutic targets and address diseases that current treatments cannot effectively reach. This strategic move positions Entact Bio to further expand its impact on precision medicine, potentially offering new hope to patients in underserved disease areas.
Heading
Key Highlights Shore Capital Partners launches Agentis Longevity to lead the longevity healthcare sector. Jimmy St Louis named CEO, bringing expertise from Regenerative Medicine ...
Key Highlights Nymbl Systems announces strategic partnership with Frontier Growth to accelerate growth and innovation. Frontier Growth brings 25+ years of growth equity expertise to ...
Key Highlights Launch of fingertip blood collection technology using BD’s MiniDraw™ and Babson’s BetterWay for U.S. health systems. Revolutionizes access with fewer ...
Key Highlights Anatomy Financial raises $19M in Series A funding, led by Canapi Ventures. Neil Underwood (Canapi) and Nicole Quinn ...
Key Highlights Wendy Barnes to assume role as GoodRx CEO on January 1, 2025. Brings 30+ years of leadership in pharmacy and healthcare benefit industries. Former CEO of RxBenefits and President of Express ...
Key Highlights Mike Butler, former Providence president, joins Linus Health's board of directors. Butler brings decades of healthcare leadership and ...
